Trial Profile
Efficacy of cabozantinib in patients with advanced renal cell carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 May 2012
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 14 Feb 2012 New trial record
- 08 Feb 2012 Preliminary results have been reported, according to an Exelixis media release.